Publicaciones en colaboración con investigadores/as de Hospital Son Llàtzer (65)

2023

  1. A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

    Respiratory Research, Vol. 24, Núm. 1

  2. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients

    Medicina Intensiva, Vol. 47, Núm. 1, pp. 23-33

  3. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

  4. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  5. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  6. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

    The Lancet Microbe, Vol. 4, Núm. 6, pp. e431-e441

  7. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis

    The European respiratory journal, Vol. 61, Núm. 3

  8. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  9. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  10. SEED Consensus Document on SpyGlass-DS

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 1, pp. 69-79

  11. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15